News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Mike Thompson: Myeloma/Plasma Cell Dyscrasia – Top Abstract Highlights from ASH24
Mike Thompson/LinkedIn
Nov 21, 2024, 16:11

Mike Thompson: Myeloma/Plasma Cell Dyscrasia – Top Abstract Highlights from ASH24

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a post on X:

 “Myeloma/Plasma Cell Dyscrasia ~ ASH24Top10 (or so) Multiple Myeloma ASH24 by Mike Thompson

*DRAFT* Table Update: Nov 20, 2024″

Mike Thompson: Myeloma/Plasma Cell Dyscrasia - Top Abstract Highlights from ASH24

 

ASH24 cancer Cell Dyscrasia Joseph Mikhael Mike Thompson multiple myeloma Myeloma OncoDaily Oncology Samer Al Hadidi Tempus
Special Coverage
Insight
Nov 21, 2024, 16:13
Unveiled an eye-opening report: ‘Under Pressure’ - ECO
Blog
Nov 21, 2024, 16:11
Mike Thompson: Myeloma/Plasma Cell Dyscrasia - Top Abstract Highlights from ASH24
Insight
Nov 21, 2024, 16:05
Francesco Maura: The Mutagenic Impact of Radiotherapy in Hematological Malignancies
Blog
Nov 21, 2024, 16:00
Mark E. Cooper will be joining SCRI to help coordinate a comprehensive breast program
Blog
Nov 21, 2024, 15:58
Thor Halfdanarson: Classic NET imaging from the Monday clinic
Insight
Nov 21, 2024, 15:54
Hiroki Hori Concludes Term as SIOP Asia President
Insight
Nov 21, 2024, 15:52
Anirban Maitra: TrialGPT in the most important benefits I see
Insight
Nov 21, 2024, 15:50
Launching an LGBTIQ and Cancer Survey - ECO
Blog
Nov 21, 2024, 15:20
Exploring Pediatric NLPHL: Insights from a Low-Middle-Income Country
Insight
Nov 21, 2024, 15:07
Consumption of aspartame and the risk of Breast Cancer in the Nurses' Health Studies
Insight
Nov 21, 2024, 15:06
Rochelle G Prosser: Day 1 of the 2nd Annual Lung Cancer Health Equity Summit is complete
Insight
Nov 21, 2024, 14:56
Samer Al Hadidi: Immune microenvironment alterations in Multiple Myeloma